[Federal Register Volume 67, Number 69 (Wednesday, April 10, 2002)]
[Notices]
[Page 17468]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-8667]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 12, 2001, Guilford 
Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 
21224, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of cocaine 
(9041) a basic class of controlled substance listed in Schedule II.
    The firm plans to manufacture methyl-3-beta-(4-
trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate 
for the production of dopascan injection.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than June 10, 2002.

    Dated: March 27, 2002.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 02-8667 Filed 4-4-02; 8:45 am]
BILLING CODE 4410-09-M